(Aziridine, Thioplex, Immunex)
of Drugs: Alkylating Agent
on Patient Assistance program: None
Solution for intravenous injection.
In order to eliminate haze, filter solutions through a 0.22 micron
filter* prior to administration. Filtering does not alter solution
potency. Reconstituted solutions should be clear. Solutions that
remain opaque or precipitate after filtration should not be used.
Adenocarcinoma of the breast or ovary.
Skin reactions associated with accidental exposure to thiotepa may
occur. The use of gloves is recommended. If thiotepa solution contacts
the skin, immediately wash the skin thoroughly with soap and water.
If thiotepa contacts mucous membranes, the membranes should be flushed
thoroughly with water.
is contraindicated in patients with a known hypersensitivity (allergy)
to this preparation.
is probably contraindicated in cases of existing hepatic, renal,
or bone-marrow damage. However, if the need outweighs the risk in
such patients, thiotepa may be used in low dosage, and accompanied
by hepatic, renal and hemopoietic function tests.
The serious complication of excessive thiotepa therapy, or sensitivity
to the effects of thiotepa, is bone-marrow depression. If proper
precautions are not observed thiotepa may cause leukopenia, thrombocytopenia,
should notify your physician in the case of any sign of bleeding
(epistaxis, easy bruising, change in color of urine, black stool)
or infection (fever, chills) or possible pregnancy.
contraception should be used during thiotepa therapy.
reactions include rash, urticaria, laryngeal edema, asthma, anaphylactic
shock, wheezing, contact dermatitis and pain at the injection site.
vomiting, abdominal pain, anorexia, decreased ability to urinate
and urinary retention may occur. There have been rare reports
of chemical cystitis or hemorrhagic cystitis following intravesical,
but not parenteral administration of thiotepa.
apnea has been reported when succinylcholine was administered prior
to surgery, following combined use of thiotepa and other anticancer
agents. It was theorized that this was caused by decrease of pseudocholinesterase
activity caused by the anticancer drugs.
may cause dizziness, headache, blurred vision, conjunctivitis, fatigue,
weakness, dermatitisand alopecia. Febrile reaction and discharge
from a subcutaneous lesion may occur as the result of breakdown
of tumor tissue. Skin depigmentation has been reported following
have also been reports of amenorrhea and thiotepa causing interference
to Drug Index
information is intended as reference and not as medical advice.
All treatment decisions should be made with your team of medical
professionals and prescriptions must be given by your doctor.